Support our Foundation of Myology project
New data on the use of enzyme replacement therapies during pregnancy and breastfeeding in Pompe disease
Partager sur
A Franco-Dutch study analysed the course of 14 pregnancies in 11 patients with Pompe disease who were being treated with alglucosidase alfa (Myozyme®) or avalglucosidase alfa (Nexviadyme®).
- No adverse effects were observed in either the mother or the child during the eight pregnancies in which treatment was continued.
- Breastfeeding whilst taking Myozyme® appears to be safe. However, the study does not provide data on breastfeeding whilst taking Nexviadyme®.
- Adjusting the dosage in line with weight gain did not prevent the slight, temporary decline in motor and respiratory function observed during pregnancy.
